☰

Ya-Ling Wu, Ph.D.

Affiliations: 
University of Chicago, Chicago, IL 
Area:
breast cancer, steroid hormone action
Google:
"Ya-Ling Wu"
Mean distance: 9.94
 		SNBCP
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
Geoffrey L. Greene grad student 2005 Chicago
 (Structural and functional characterization of human estrogen receptor alpha ligand -binding domain in complex with GW5638.)

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Zhou Q, Xu CR, Cheng Y, et al. (2021) Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell
Passaro A, de Marinis F, Tu HY, et al. (2021) Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. Frontiers in Oncology. 11: 709877
Tu HY, Li YS, Yang JJ, et al. (2021) Long-Term Survival of Over 6 Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report. Clinical Drug Investigation
Ni J, Huang M, Zhang L, et al. (2021) Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer. Thoracic Cancer
Wu YL, Smit EF, Bauer TM. (2021) Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies. Cancer Treatment Reviews. 95: 102173
Tang WF, Wu M, Bao H, et al. (2021) Timing and origins of local and distant metastases in lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer
Cheng Y, Mok TS, Zhou X, et al. (2021) Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer (Amsterdam, Netherlands). 154: 176-185
Zhang L, Lu S, Cheng Y, et al. (2021) Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial. Annals of Translational Medicine. 9: 338
Kok PS, Lee K, Lord S, et al. (2021) Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis. Lung Cancer (Amsterdam, Netherlands). 154: 113-117
Herbst RS, Wu YL, Tsuboi M. (2021) Osimertinib in EGFR-Mutated Lung Cancer. Reply. The New England Journal of Medicine. 384: 675-676
See more...